Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice.

Journal of the European Academy of Dermatology and Venereology : JEADV Jul 2022

Description

Dupilumab is the first biotherapy available for the treatment of moderate-to-severe childhood atopic dermatitis (AD).